See All Slides - tctmd.com

Slides

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Presenter: Eberhard Grube, Michael J. Mack

October 11, 2015

Presentation TCT 2015

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Presenter: Thomas Engstroem, Barry D. Rutherford, Colin Berry

October 11, 2015

Presentation TCT 2015

Which NOAC for Which Patient?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Christopher B. Granger

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Device-Based Therapies for Hypertension Treatment: Procedural Aspects

Presenter: Ajay J. Kirtane, Felix Mahfoud, Farrell O. Mendelsohn

October 11, 2015

Presentation TCT 2015

Updated Meta-analysis of Culprit Only vs Complete Revascularization in STEMI: Are We Impacting Death and Reinfarction or Repeat Revascularization Only?

Presenter: Thomas Engstroem, Barry D. Rutherford, Anthony H. Gershlick

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

A Bioskills Primer for Mitral Valve Device Inventors and Interventionalists

Presenter: Patrick T. O'Gara, Allan Schwartz, Mark Reisman

October 11, 2015

Presentation TCT 2015

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

Presenter: Eberhard Grube, Michael J. Mack, Raj Makkar

October 11, 2015

Presentation TCT 2015

The Antegrade Approach: J-CTO Registry Insights

Presenter: J. Aaron Grantham, Masahiko Ochiai, Masahisa Yamane

October 11, 2015

Advertisement

Slides

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Which NOAC for Which Patient?

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Device-Based Therapies for Hypertension Treatment: Procedural Aspects

Updated Meta-analysis of Culprit Only vs Complete Revascularization in STEMI: Are We Impacting Death and Reinfarction or Repeat Revascularization Only?

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

A Bioskills Primer for Mitral Valve Device Inventors and Interventionalists

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

The Antegrade Approach: J-CTO Registry Insights

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content